FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.
/ 352 items
#XY Event-Driven Stocks↓
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Cocrystal Pharma Gets FDA Fast Track for Norovirus Treatment & Prevention
FDA fast-tracks a new oral drug, CDI-988, to treat and prevent norovirus—a common stomach virus affecting millions worldwide.
Lipocine’s Oral PPD Pill Shows Strong Promise in Key Group Despite Missing Main Goal
Lipocine’s oral pill for postpartum depression missed main goal but showed fast, lasting benefits in some patients with good safety profile.
ALTO-101 Misses Primary Endpoint in Schizophrenia Trial, Company Shifts Focus to ALTO-207
ALTO-101 misses Phase 2 endpoints but shows signals. Alto pivots to ALTO-207 in treatment-resistant depression with strong prior data.
Connect Biopharma Insider Buying: Panacea Venture Adds 1.16M Shares
Director James Huang and Panacea Venture bought 1.16 million shares of Connect Biopharma at $3.45, boosting their stake to 21.2%.